Kimyrsa is a Intravenous Injection, Powder, Lyophilized, For Solution in the Human Prescription Drug category. It is labeled and distributed by Melinta Therapeutics, Llc. The primary component is Oritavancin Diphosphate.
Product ID | 70842-225_177809df-e595-441f-98cb-90f60a3bc11e |
NDC | 70842-225 |
Product Type | Human Prescription Drug |
Proprietary Name | Kimyrsa |
Generic Name | Oritavancin Diphosphate |
Dosage Form | Injection, Powder, Lyophilized, For Solution |
Route of Administration | INTRAVENOUS |
Marketing Start Date | 2021-03-23 |
Marketing Category | NDA / |
Application Number | NDA214155 |
Labeler Name | Melinta Therapeutics, LLC |
Substance Name | ORITAVANCIN DIPHOSPHATE |
Active Ingredient Strength | 1200 mg/40mL |
Pharm Classes | Lipoglycopeptide Antibacterial [EPC],Lipoglycopeptides [EXT],Cytochrome P450 2C19 Inhibitors [MoA],Cytochrome P450 2C9 Inhibitors [MoA],Cytochrome P450 3A4 Inducers [MoA],Cytochrome P450 2D6 Inducers [MoA] |
NDC Exclude Flag | N |
Listing Certified Through | 2022-12-31 |
Marketing Start Date | 2021-03-23 |
NDC Exclude Flag | N |
Sample Package? | N |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
KIMYRSA 90039970 not registered Live/Pending |
Melinta Therapeutics, Inc. 2020-07-07 |